LabCorp Clinical Trials, European Kit Building Operation Sustainability Profile
LabCorp Clinical Trials, a division of Laboratory Corporation of America Holdings, is a leading player in the clinical research industry, headquartered in Germany (DE). Established in 1971, LabCorp has evolved into a global powerhouse, specialising in clinical trial services, laboratory testing, and diagnostic solutions. The European Kit Building Operation is a key component of LabCorp's extensive service offerings, providing customised kits for clinical trials across various therapeutic areas. This operation stands out for its commitment to quality and efficiency, ensuring that trial materials are tailored to meet specific regulatory requirements. With a strong market position, LabCorp Clinical Trials has achieved numerous milestones, including partnerships with major pharmaceutical companies and a reputation for delivering reliable results. Their innovative approach and dedication to advancing healthcare make them a trusted partner in the clinical research landscape.
DitchCarbon Score
How does LabCorp Clinical Trials, European Kit Building Operation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
LabCorp Clinical Trials, European Kit Building Operation's score of 22 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
LabCorp Clinical Trials, European Kit Building Operation, currently does not have specific carbon emissions data available for the most recent year. As a merged entity, it inherits emissions data and climate commitments from its parent company, Marken Limited, at cascade level 1. However, no specific reduction targets or climate pledges have been documented for this operation. The organisation's climate commitments are influenced by its relationship with United Parcel Service, Inc. (UPS), from which it inherits broader emissions data at cascade level 5. Despite the absence of detailed emissions figures, the commitment to sustainability is evident through the corporate family structure, which prioritises climate action. LabCorp Clinical Trials is positioned within an industry that increasingly emphasises the importance of reducing carbon footprints and adhering to science-based targets. As the organisation continues to align with its parent company's initiatives, it remains focused on enhancing its environmental performance in the future.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | 2023 | |
|---|---|---|
| Scope 1 | 2,842,000 | 0,000,000 |
| Scope 2 | 3,916,000 | 0,000,000 |
| Scope 3 | 64,048,000 | 00,000,000 |
How Carbon Intensive is LabCorp Clinical Trials, European Kit Building Operation's Industry?
How Carbon Intensive is LabCorp Clinical Trials, European Kit Building Operation's Location?
LabCorp Clinical Trials, European Kit Building Operation's Scope 3 Categories Breakdown
LabCorp Clinical Trials, European Kit Building Operation's Scope 3 emissions, which increased by 3% last year and increased by approximately 3% since 2022, demonstrating supply chain emissions tracking. The vast majority of their carbon footprint comes from suppliers and value chain emissions, representing the vast majority of total emissions under the GHG Protocol, with "Employee Commuting" being the largest emissions source at 3% of Scope 3 emissions.
Top Scope 3 Categories
LabCorp Clinical Trials, European Kit Building Operation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
LabCorp Clinical Trials, European Kit Building Operation has established climate goals through participation in recognized frameworks and target-setting initiatives. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.